Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study.
<h4>Aim</h4>To evaluate the effectiveness of non-aromatic very rich in steranes (NAVS) naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Null hypothesis was that there would be no difference between NAVS and topical steroids in the treatment...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0249862 |
| _version_ | 1818719353095323648 |
|---|---|
| author | Ana Andabak Rogulj Iva Z Alajbeg Vlaho Brailo Ivana Škrinjar Ivona Žužul Vanja Vučićević-Boras Ivan Alajbeg |
| author_facet | Ana Andabak Rogulj Iva Z Alajbeg Vlaho Brailo Ivana Škrinjar Ivona Žužul Vanja Vučićević-Boras Ivan Alajbeg |
| author_sort | Ana Andabak Rogulj |
| collection | DOAJ |
| description | <h4>Aim</h4>To evaluate the effectiveness of non-aromatic very rich in steranes (NAVS) naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Null hypothesis was that there would be no difference between NAVS and topical steroids in the treatment of OLP and RAS.<h4>Methods</h4>The study consisted of two sub-trials conducted as randomized, double-blind controlled studies: first included OLP patients and second patients with RAS. Patients received either NAVS or 0.05% betamethasone dipropionate. Primary outcomes were activity score (OLP patients), No of lesions and lesion diameter (RAS patients) and pain intensity (VAS) while secondary outcome included the impact of the disease on quality of life assessed by Oral health impact profile (OHIP 14).<h4>Results</h4>No significant differences in terms of OLP clinical signs (p = 0.84, η2 = 0.001) and responses on the OHIP-14 (p = 0.81, η2 = 0.002) or on VAS (p = 0.14, η2 = 0.079) between NAVS and betamethasone groups were observed. In RAS patients, no significant differences between the groups in terms of lesion number (at days 3 and 5, p = 0.33 and p = 0.98, respectively), lesion diameter (days 3 and 5, p = 0.24 and p = 0.84, respectively) were observed. However, in NAVS group a significant reduction of lesions diameter was observed on the 3rd day, while in betamethasone group a significant reduction in lesions diameter was evident only after the 5th day. No significant differences in VAS (p > 0.05) and the OHIP-14 (p > 0.05) between groups were found.<h4>Conclusion</h4>No evidence of differences between the two compared interventions was found.<h4>Registration</h4>Retrospective registration of this trial was conducted in ClinicalTrials.gov on September 30, 2016; trial registration number: NCT02920658. https://clinicaltrials.gov/ct2/show/NCT02920658?term=NAVS&draw=2&rank=4. |
| first_indexed | 2024-12-17T20:05:35Z |
| format | Article |
| id | doaj.art-ac12ca3b01d24455a1c232842b9d44a2 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T20:05:35Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ac12ca3b01d24455a1c232842b9d44a22022-12-21T21:34:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01164e024986210.1371/journal.pone.0249862Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study.Ana Andabak RoguljIva Z AlajbegVlaho BrailoIvana ŠkrinjarIvona ŽužulVanja Vučićević-BorasIvan Alajbeg<h4>Aim</h4>To evaluate the effectiveness of non-aromatic very rich in steranes (NAVS) naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Null hypothesis was that there would be no difference between NAVS and topical steroids in the treatment of OLP and RAS.<h4>Methods</h4>The study consisted of two sub-trials conducted as randomized, double-blind controlled studies: first included OLP patients and second patients with RAS. Patients received either NAVS or 0.05% betamethasone dipropionate. Primary outcomes were activity score (OLP patients), No of lesions and lesion diameter (RAS patients) and pain intensity (VAS) while secondary outcome included the impact of the disease on quality of life assessed by Oral health impact profile (OHIP 14).<h4>Results</h4>No significant differences in terms of OLP clinical signs (p = 0.84, η2 = 0.001) and responses on the OHIP-14 (p = 0.81, η2 = 0.002) or on VAS (p = 0.14, η2 = 0.079) between NAVS and betamethasone groups were observed. In RAS patients, no significant differences between the groups in terms of lesion number (at days 3 and 5, p = 0.33 and p = 0.98, respectively), lesion diameter (days 3 and 5, p = 0.24 and p = 0.84, respectively) were observed. However, in NAVS group a significant reduction of lesions diameter was observed on the 3rd day, while in betamethasone group a significant reduction in lesions diameter was evident only after the 5th day. No significant differences in VAS (p > 0.05) and the OHIP-14 (p > 0.05) between groups were found.<h4>Conclusion</h4>No evidence of differences between the two compared interventions was found.<h4>Registration</h4>Retrospective registration of this trial was conducted in ClinicalTrials.gov on September 30, 2016; trial registration number: NCT02920658. https://clinicaltrials.gov/ct2/show/NCT02920658?term=NAVS&draw=2&rank=4.https://doi.org/10.1371/journal.pone.0249862 |
| spellingShingle | Ana Andabak Rogulj Iva Z Alajbeg Vlaho Brailo Ivana Škrinjar Ivona Žužul Vanja Vučićević-Boras Ivan Alajbeg Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. PLoS ONE |
| title | Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. |
| title_full | Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. |
| title_fullStr | Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. |
| title_full_unstemmed | Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. |
| title_short | Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. |
| title_sort | topical navs naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis a double blind randomized parallel group study |
| url | https://doi.org/10.1371/journal.pone.0249862 |
| work_keys_str_mv | AT anaandabakrogulj topicalnavsnaphthalanforthetreatmentoforallichenplanusandrecurrentaphthousstomatitisadoubleblindrandomizedparallelgroupstudy AT ivazalajbeg topicalnavsnaphthalanforthetreatmentoforallichenplanusandrecurrentaphthousstomatitisadoubleblindrandomizedparallelgroupstudy AT vlahobrailo topicalnavsnaphthalanforthetreatmentoforallichenplanusandrecurrentaphthousstomatitisadoubleblindrandomizedparallelgroupstudy AT ivanaskrinjar topicalnavsnaphthalanforthetreatmentoforallichenplanusandrecurrentaphthousstomatitisadoubleblindrandomizedparallelgroupstudy AT ivonazuzul topicalnavsnaphthalanforthetreatmentoforallichenplanusandrecurrentaphthousstomatitisadoubleblindrandomizedparallelgroupstudy AT vanjavucicevicboras topicalnavsnaphthalanforthetreatmentoforallichenplanusandrecurrentaphthousstomatitisadoubleblindrandomizedparallelgroupstudy AT ivanalajbeg topicalnavsnaphthalanforthetreatmentoforallichenplanusandrecurrentaphthousstomatitisadoubleblindrandomizedparallelgroupstudy |